Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy

CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in patients with relapsed/refractory B-cell malignancies; however, it is associated with toxicities including cytokine release syndrome (CRS), neurotoxicity, and impaired hematopoietic recovery. The lat...

Descripción completa

Detalles Bibliográficos
Autores principales: Juluri, Krishna R., Wu, Qian Vicky, Voutsinas, Jenna, Hou, Jue, Hirayama, Alexandre V., Mullane, Erin, Miles, Nancy, Maloney, David G., Turtle, Cameron J., Bar, Merav, Gauthier, Jordan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006285/
https://www.ncbi.nlm.nih.gov/pubmed/34666344
http://dx.doi.org/10.1182/bloodadvances.2020004142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006285/
https://www.ncbi.nlm.nih.gov/pubmed/34666344
http://dx.doi.org/10.1182/bloodadvances.2020004142

Ejemplares similares